Login to Your Account



Immatics, Roche Ink Potential $1B Cancer Immunotherapy Deal

By Nuala Moran
Staff Writer

Wednesday, November 13, 2013
LONDON – Immatics Biotechnologies GmbH signed up Roche AG in a wide-ranging collaboration that boasts a headline value of $1 billion and ushers the company’s cancer immunotherapy platform into the pharmaceutical mainstream.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription